{
    "clinical_study": {
        "@rank": "168154", 
        "arm_group": {
            "arm_group_label": "GORE\u00ae EXCLUDER\u00ae Iliac Branch Endoprosthesis", 
            "arm_group_type": "Experimental", 
            "description": "GORE\u00ae EXCLUDER\u00ae Iliac Branch Endoprosthesis"
        }, 
        "brief_summary": {
            "textblock": "The Iliac Branch Endoprosthesis (IBE) 12-04 study will be a prospective, nonrandomized,\n      multicenter, single-arm evaluation designed to assess the safety and efficacy of the IBE\n      Device in subjects with common iliac artery aneurysms (CIAA) or aorto-iliac aneurysms (AIA)."
        }, 
        "brief_title": "Evaluation of the GORE\u00ae EXCLUDER\u00ae Iliac Branch Endoprosthesis", 
        "condition": [
            "Common Iliac Artery Aneurysms", 
            "Aorto-iliac Aneurysms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Aneurysm", 
                "Iliac Aneurysm"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Common iliac aneurysm with or without concomitant abdominal aortic aneurysm\n\n          2. Adequate native anatomy to receive the EXCLUDER\u00ae and Iliac Branch Endoprostheses\n\n          3. An Informed Consent Form signed by Subject or legally authorized representative\n\n          4. Male or infertile female\n\n          5. Able to comply with protocol requirements including following-up\n\n          6. Life expectancy > 2 years\n\n          7. Age > 21 years\n\n          8. Surgical candidate\n\n        Exclusion Criteria:\n\n          1. Mycotic or ruptured aneurysm\n\n          2. Known concomitant thoracic aortic aneurysm which requires intervention\n\n          3. American Society of Anesthesiologists (ASA) Physical Status classification system\n             class V (moribund patient not expected to live 24 hours with or without operation)\n\n          4. Renal insufficiency defined or patient undergoing dialysis\n\n          5. New York Heart Association (NYHA) Functional Classification class IV\n\n          6. Dissected, heavily calcified, or heavily thrombosed landing zone(s)\n\n          7. Tortuous or stenotic iliac and/or femoral arteries\n\n          8. Participating in another investigational device or drug study within 1 year of\n             treatment\n\n          9. Systemic infection which may increase the risk of endovascular graft infection\n\n         10. Known degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome\n\n         11. Planned concomitant surgical procedure or major surgery within 30 days of treatment\n             date\n\n         12. Known history of drug abuse\n\n         13. Known sensitivities or allergies to the device materials"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01883999", 
            "org_study_id": "IBE 12-04"
        }, 
        "intervention": {
            "arm_group_label": "GORE\u00ae EXCLUDER\u00ae Iliac Branch Endoprosthesis", 
            "intervention_name": "GORE\u00ae EXCLUDER\u00ae Iliac Branch Endoprosthesis", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Weill Cornell Medical Center"
            }, 
            "investigator": {
                "last_name": "Darren Schneider, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of the GORE\u00ae EXCLUDER\u00ae Iliac Branch Endoprosthesis for the Treatment of Common Iliac Artery Aneurysms or Aorto-iliac Aneurysms", 
        "overall_contact": {
            "email": "npirooz@wlgore.com", 
            "last_name": "Nick Pirooz, MHA", 
            "phone": "(623) 234-5519"
        }, 
        "overall_official": {
            "affiliation": "Weill Medical College of Cornell University", 
            "last_name": "Darren Schneider, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Composite of the following: Death, Stroke, Myocardial Infarction, Bowel Ischemia,Paraplegia, Respiratory Failure, Renal Failure,Conversion to open surgical repair.", 
            "measure": "Primary Safety Endpoint", 
            "safety_issue": "Yes", 
            "time_frame": "30 days post-treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01883999"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "W.L.Gore & Associates", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "W.L.Gore & Associates", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}